Alnylam Pharmaceuticals Inc
(HAM:DUL)
€
272.5
-1.5 (-0.55%)
Market Cap: 36.70 Bil
Enterprise Value: 35.18 Bil
PE Ratio: 85.53
PB Ratio: 38.84
GF Score: 74/100 Alnylam Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
Mar 16, 2023 / 12:00PM GMT
Release Date Price:
€173.56
(+0.34%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst
Good morning, everyone. My name is Gena Wang. I'm SMID-cap biotech analyst at Barclays. Welcome to Barclays Global Healthcare Conference. Today is the last day, and I hope everyone had a very productive meetings -- all having additional productive meetings. It is my great pleasure to introduce today's first presenting company, Alnylam. With us today, we have Jeff Poulton, Chief Financial Officer; also Eric Green, SVP, Head of Development Profiles. Thank you for coming to our conference.
Jeffrey V. Poulton
Alnylam Pharmaceuticals, Inc. - CFO & Executive VP
Thank you. Thanks to Barclays for having us. It's always nice to be in Miami in this time of year.
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst
Yes, certainly better than Boston.
Jeffrey V. Poulton
Alnylam Pharmaceuticals, Inc. - CFO & Executive VP
Much better.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |

30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot